Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors (NCT06545942)
A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.
Who can join: Review the eligibility criteria below.
Location: Investigative Site #108 — Goodyear, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- Investigative Site #108 — Goodyear, Arizona
- Investigative Site #101 — La Jolla, California
- Investigative Site #111 — San Francisco, California
- Investigative Site #104 — Lake Mary, Florida
- Investigative Site #110 — St Louis, Missouri
- Investigative Site #103 — New York, New York
- Investigative Site #106 — New York, New York
- Investigative Site #109 — Philadelphia, Pennsylvania
- Investigative Site #107 — Myrtle Beach, South Carolina
- Investigative Site #102 — Nashville, Tennessee
- Investigative Site #105 — San Antonio, Texas
- Investigative Site #112 — Fairfax, Virginia
- Investigative Site #114 — Barcelona,
- Investigative Site #116 — Barcelona,
- Investigative Site #115 — Madrid,
- Investigative Site #113 — London,
- Investigative Site #117 — Manchester,
- Investigative Site #118 — Newcastle upon Tyne,
📞 Contact the Study Coordinator
Phone: (857) 285-3677
Email: clinicaltrials@momatx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumor
- Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
- A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
- QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
- A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
- First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
- A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas
Explore by condition: All Advanced Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.